These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 28870636)

  • 1. De novo ERBB2 amplification causing intrinsic resistance to erlotinib in EGFR-L858R mutated TKI-naïve lung adenocarcinoma.
    Carney BJ; Rangachari D; VanderLaan PA; Gowen K; Schrock AB; Ali SM; Costa DB
    Lung Cancer; 2017 Dec; 114():108-110. PubMed ID: 28870636
    [No Abstract]   [Full Text] [Related]  

  • 2. Acquired Resistance to Erlotinib in EGFR Mutation-Positive Lung Adenocarcinoma among Hispanics (CLICaP).
    Cardona AF; Arrieta O; Zapata MI; Rojas L; Wills B; Reguart N; Karachaliou N; Carranza H; Vargas C; Otero J; Archila P; Martín C; Corrales L; Cuello M; Ortiz C; Pino LE; Rosell R; Zatarain-Barrón ZL;
    Target Oncol; 2017 Aug; 12(4):513-523. PubMed ID: 28620690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.
    Lou W; Chen Y; Zhu KY; Deng H; Wu T; Wang J
    Biol Pharm Bull; 2017 Aug; 40(8):1306-1313. PubMed ID: 28515374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coexistence of tyrosine kinase inhibitor-sensitizing and resistant EGFR mutations in an untreated lung adenocarcinoma patient and response to erlotinib.
    Mathur G; Ma D
    J Thorac Oncol; 2014 Jul; 9(7):e55-e57. PubMed ID: 24926557
    [No Abstract]   [Full Text] [Related]  

  • 5. Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib.
    Naidoo J; Sima CS; Rodriguez K; Busby N; Nafa K; Ladanyi M; Riely GJ; Kris MG; Arcila ME; Yu HA
    Cancer; 2015 Sep; 121(18):3212-3220. PubMed ID: 26096453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.
    Kim MH; Kim HR; Cho BC; Bae MK; Kim EY; Lee CY; Lee JS; Kang DR; Kim JH
    Lung Cancer; 2014 May; 84(2):196-202. PubMed ID: 24629638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.
    Yu HA; Arcila ME; Rekhtman N; Sima CS; Zakowski MF; Pao W; Kris MG; Miller VA; Ladanyi M; Riely GJ
    Clin Cancer Res; 2013 Apr; 19(8):2240-7. PubMed ID: 23470965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study.
    Lee JH; Lee HY; Ahn MJ; Park K; Ahn JS; Sun JM; Lee KS
    Cancer Imaging; 2016 Mar; 16():5. PubMed ID: 26984681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring EGFR TKI resistance in real time using ddPCR-based liquid biopsy: a case report.
    Sorber L; Zwaenepoel K; Wouters A; Janssens A; Hiddinga B; Van Meerbeeck J; Lardon F; Pauwels P; Rolfo C
    J Clin Pathol; 2018 Aug; 71(8):754-756. PubMed ID: 29853531
    [No Abstract]   [Full Text] [Related]  

  • 10. The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy.
    Yang CJ; Hung JY; Tsai MJ; Wu KL; Liu TC; Chou SH; Lee JY; Hsu JS; Huang MS; Chong IW
    BMC Pharmacol Toxicol; 2017 May; 18(1):21. PubMed ID: 28486985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.
    Takezawa K; Pirazzoli V; Arcila ME; Nebhan CA; Song X; de Stanchina E; Ohashi K; Janjigian YY; Spitzler PJ; Melnick MA; Riely GJ; Kris MG; Miller VA; Ladanyi M; Politi K; Pao W
    Cancer Discov; 2012 Oct; 2(10):922-33. PubMed ID: 22956644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy of erlotinib/crizotinib in a lung adenocarcinoma patient with primary EGFR mutation plus secondary MET amplification and a novel acquired crizotinib-resistant mutation MET G1108C.
    Li YQ; Song SS; Jiang SH; Zhang XY
    Ann Oncol; 2017 Oct; 28(10):2622-2624. PubMed ID: 28961830
    [No Abstract]   [Full Text] [Related]  

  • 13. Successful Treatment of Non-Small Cell Lung Cancer With Erlotinib Throughout Pregnancy.
    Ji Y; Schwartz J; Hartford A; Ramsey J; Phillips J; Verschraegen C
    JAMA Oncol; 2015 Sep; 1(6):838-40. PubMed ID: 26181671
    [No Abstract]   [Full Text] [Related]  

  • 14. EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.
    Yu G; Xie X; Sun D; Geng J; Fu F; Zhang L; Wang H
    Int J Clin Exp Pathol; 2015; 8(7):8603-6. PubMed ID: 26339441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib.
    Sato M; Matsui A; Shimoyama Y; Omote N; Morise M; Hase T; Tanaka I; Suzuki K; Hasegawa Y
    Intern Med; 2018 Dec; 57(23):3429-3432. PubMed ID: 30101911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.
    Costa DB; Nguyen KS; Cho BC; Sequist LV; Jackman DM; Riely GJ; Yeap BY; Halmos B; Kim JH; Jänne PA; Huberman MS; Pao W; Tenen DG; Kobayashi S
    Clin Cancer Res; 2008 Nov; 14(21):7060-7. PubMed ID: 18981003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic Metastases is Associated with Poor Efficacy of Erlotinib as 2nd/3rd Line Therapy in Patients with Lung Adenocarcinoma.
    He Y; Wang Y; Boyle T; Ren S; Chan D; Rivard C; Li X; Li J; Zhou C; Hirsch FR
    Med Sci Monit; 2016 Jan; 22():276-83. PubMed ID: 26811313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genome-wide DNA Methylation Analysis Reveals
    Niu X; Liu F; Zhou Y; Zhou Z; Zhou D; Wang T; Li Z; Ye X; Yu Y; Weng X; Zhang H; Ye J; Liao M; Liu Y; Chen Z; Lu S
    Clin Cancer Res; 2017 Sep; 23(17):5003-5014. PubMed ID: 28490462
    [No Abstract]   [Full Text] [Related]  

  • 19. A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (
    Han JY; Lee KH; Kim SW; Min YJ; Cho E; Lee Y; Lee SH; Kim HY; Lee GK; Nam BH; Han H; Jung J; Lee JS
    Cancer Res Treat; 2017 Jan; 49(1):10-19. PubMed ID: 27188206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of BIBW2992 and ARQ 197 is effective against erlotinib-resistant human lung cancer cells with the EGFR T790M mutation.
    Qu G; Liu C; Sun B; Zhou C; Zhang Z; Wang P
    Oncol Rep; 2014 Jul; 32(1):341-7. PubMed ID: 24842595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.